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ABSTRACT
Objective: To evaluate the prevalence of and the associated factors for metabolic syndrome (MS) 
among Latin American HIV-infected patients receiving antiretroviral therapy (ART) using baseline 
data from the RAPID II study. Methods: A longitudinal study to evaluate the metabolic profi le, 
cardiovascular disease (CVD) risk and associated treatment practices to reduce this risk has been 
conducted in seven Latin American countries (the RAPID II study). Adult HIV patients with at least 
six months of RT were enrolled. MS was defi ned following ATP-III criteria. Demographic and an-
thropometric data, serum biochemical and clinical parameters were compared in patients with and 
without MS using bivariate and multivariate analysis. Results: A total of 4,010 patients were enrolled, 
2,963 (74%) were males. Mean age (SD) was 41.9 (10.0) years. The prevalence of MS was 20.2%. 
Females had higher prevalence of MS than males (22.7% vs. 19.4%, p = 0.02). MS was driven by high 
triglycerides, low HDL-cholesterol and high blood pressure (HBP). Patients with MS had higher 10-
year CVD risk: 22.2% vs. 7.4%, p < 0.001. Age (OR: 1.05 per year), female gender (OR: 1.29), family 
history of CVD (OR: 1.28), CD4 cell count (OR: 1.09 per 100 cell increase), and protease inhibitor 
based-ART (OR: 1.33) correlated with MS in the multivariate analysis. Conclusions: Prevalence of 
MS in this setting was similar to that reported from developed countries. MS was driven by high trig-
lycerides, low-HDL and HBP, and it was associated with higher risk of CVD. Traditional risk factors, 
female gender, immune reconstitution, and protease inhibitor based-ART correlated with MS.
Keywords: metabolic syndrome (MS), HIV, ART, Latin America.
[Braz J Infect Dis 2010;14(3):256-263]©Elsevier Editora Ltda.
INTRODUCTION
Metabolic syndrome (MS) includes derange-
ments in glucose metabolism, insulin resistance, 
lipid abnormalities, hypertension and abdomi-
nal obesity.1 Patients with MS from the general 
population have more risk to develop type 2 di-
abetes and carry a signifi cant increased risk of 
dying due to cardiovascular disease (CVD).2,3 
Therefore, identifying individuals with MS may 
allow implementation of measures to halt the 
progression to diabetes and CVD. 
Since the introduction of effective antivi-
ral treatment through combined antiretroviral 
therapy (RT) in the 1990s, a signifi cant im-
provement in survival of HIV-infected patients 
has been observed, together with a dramatic de-
crease in the incidence of many opportunistic 
infections.4 However, metabolic abnormalities 
and abnormal body fat redistribution, follow-
ing a very similar pattern to that described for 
MS, were soon observed.5,6 In addition, several 
early studies disclosed that HIV-infected pa-
tients receiving ART had high prevalence rates 
of MS, even higher than those reported from 
the general population in certain settings.7-9 
While the real contribution of MS to detect 
patients at risk to develop CVD compared to 
other traditional risk evaluations in both non-
HIV and HIV-infected populations is currently 
under debate, most experts agree that com-
ponents of MS may be used to predict risk of 
CVD and type 2 diabetes mellitus.1,10 
Scaling-up programs to provide ART are 
being implemented across the world thanks 
to initiatives promoted by several organiza-
tions. The net results of these interventions is 
a marked benefi t in survival and quality of life 
among ART recipients, but it is also expected 
that all short and long-term complications of 
ART, including metabolic abnormalities will be 
observed in these patients, although the magni-
tude of the problem has not been explored yet. 
Latin American countries are not the exception 
of this situation, as reported by WHO using 
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data up to 2007; approximately 300,000 patients received 
ART in Latin America that year.11 Therefore, we undertook 
this study to evaluate the prevalence and determinants of 
metabolic syndrome among Latin American HIV-infected 
patients receiving ART, using baseline data gathered from 
the RAPID II study. The results of this study may be used 
by regional and local policy makers to incorporate interven-
tions aimed at reducing the burden of long-term metabolic 
complications of ART in the region.
 
METHODS
Study design
The RAPID II study (Registry and Prospective Analysis of 
Patients Infected with HIV and Dyslipidemia) is a cohort 
web-based study designed to prospectively collect data on 
demographic, metabolic and treatment modalities among 
HIV-infected patients receiving ART in Latin America. 
Setting
Sixty one centers from seven Latin American countries are 
participating in the study: Argentina (16 centers in Buenos 
Aires, La Plata and Rosario), Brazil (15 centers in Sao Paulo, 
Rio de Janeiro, Campinas, and Porto Alegre), Chile (2 cent-
ers in Santiago), Colombia (3 centers in Bogotá and Cali), 
Ecuador (11 centers in Quito, Cuenca and Guayaquil), Peru 
(5 centers in Lima) and Venezuela (9 centers in Caracas, Va-
lencia, Barquisimeto and San Cristobal).
Study population
Inclusion criteria: Patients older than 18 years of age, or 
minimum age as determined by local regulations or as legal 
requirements dictate, of both genders, and with confi rmed 
HIV infection receiving ART for at least six months prior to 
enrollment were selected. A lipid profi le had to be obtained 
on every patient at enrollment or within one month. All 
patients had to be managed as outpatients from November 
2006 to September 2007. 
Exclusion criteria: Patients were excluded if they had been 
enrolled in any clinical trial within one month before enroll-
ment or if written consent was not granted.
Procedures
A detailed interview was performed at enrollment to obtain 
demographic data; details of HIV infection, including time 
from diagnosis to enrollment and history of current and 
prior antiretroviral medications. Cardiovascular risk factors 
present before enrollment including history of hypertension, 
diabetes mellitus, dyslipidemia, smoking habit, and family 
history of premature CVD. Information on smoking, exer-
cising and diet, as well as on any medication or lipid lower-
ing intervention implemented during the two months prior 
to enrollment was also obtained. Patients who had a history 
of dyslipidemia were requested to provide information on 
any prior lipid intervention undertaken, including diet, ex-
ercise and the use of lipid lowering drugs. A complete physi-
cal examination was performed, including measurements of 
blood pressure, weight, height, and waist circumference. A 
fasting blood sample was taken and processed in each par-
ticipating centre to measure blood glucose, total cholesterol, 
HDL-cholesterol and LDL-cholesterol, triglycerides, creat-
ine phosphokinase, and liver enzymes, including AST and 
ALT, at enrollment and every six months for two years. CD4 
cell count and viral load determination were also performed 
at enrollment and every six months for two years.
Deﬁ nition of metabolic syndrome 
The main outcome of this study was to determine the preva-
lence and the determinants of metabolic syndrome at the 
fi rst study visit. Metabolic syndrome was defi ned following 
National Cholesterol Education Program Adult Treatment 
Panel III defi nition.1 Based on that defi nition, three or more 
of the following criteria need to be met for defi ning meta-
bolic syndrome: 1) fasting serum triglycerides ≥ 150 mg/dL; 
2) abnormal waist circumference: waist perimeter ≥ 102 cm 
in man, or ≥ 88 cm in women); 3) fasting blood glucose ≥ 
100 mg/dL; 4) hypertension: systolic blood pressure ≥ 130 
mmHg and/or diastolic blood pressure ≥ 85 mmHg, and/or 
use of an antihypertensive drug); 5) low HDL-cholesterol: 
man with ≤ 40 mg/dL or woman with ≤ 50 mg/dL. 
Statistical analysis
Demographic and clinical variables were compared between 
patients with and without metabolic syndrome including 
age, gender, family history of CVD, body mass index, obes-
ity, current smoking, lack of exercise, duration of HIV infec-
tion, time on ART, current use of protease inhibitors (PI), 
current use of nucleoside reverse transcriptase inhibitors 
(NRTI) and non-nucleoside reverse transcriptase inhibi-
tors (NNRTI), CD4 cell count, viral load determination, and 
serum biochemical evaluations including glucose and lipid 
parameters. The Framingham risk algorithm was used to es-
timate the 10-year risk of developing CVD. 
Categorical variables were contrasted with the chi-square 
test with continuity correction or with the Fisher´s exact test. 
Continuous variables were contrasted with the student´s t-
test or the Mann-Whitney test. All tests were two sided, the 
level of signifi cance was pre-defi ned at < 0.05. Odds ratios 
and 95% confi dence intervals were calculated. Associated 
factors for metabolic syndrome were evaluated in bivariate 
and multivariate analysis following backward stepwise un-
conditional regression analysis. 
Ethical considerations
The study was approved by local and national regulatory 
agencies in each participating center. Each patient signed an 
informed consent form.
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RESULTS
A total of 4,010 patients were recruited, Argentina en-
rolled 1,015 patients, Brazil enrolled 1,001 patients and 
Venezuela enrolled 807 patients. The remaining patients 
were enrolled by Colombia (474 patients), Peru (417 pa-
tients), Ecuador (252 patients) and Chile (44 patients). 
Mean age (SD) of the population was 41.9 (10.0) years, 
73.9% of the patients were males. Most of the patients 
were concentrated in the age group of 28-47 years; only 
1.5% had more than 68 years of age. Median CD4 cell 
count was 417 cells/mm3 (IQR: 266-621), and mean vi-
ral load determination was 2.4 (1.0) log
10
 copies/mL. A 
protease inhibitor based ART was used in 44% of pa-
tients.
The overall prevalence of MS was 20.2% (812/4,010); 
it was higher in female than in male patients: 22.7% vs. 
19.4%, respectively, p = 0.02. The distribution of in-
dividual components of the MS by gender is shown in 
Figure 1. High triglycerides (55.8%), low-HDL choles-
terol (49.5%) and hypertension (31.5%) were the most 
prevalent individual components of MS in this popula-
tion. Male patients had higher prevalence of hypertrig-
lyceridemia, elevated fasting blood glucose and hyper-
tension than females. In contrast, female patients had 
higher prevalence of low-HDL cholesterol and abdomi-
nal obesity than male patients. 
Figure 1: Components of the metabolic syndrome by gender.
Figure 2: Prevalence of metabolic syndrome by age and 
gender.
Figure 3: Prevalence of metabolic syndrome by country and 
gender.
The prevalence of MS by age and gender is shown in 
Figure 2. A trend towards higher prevalence rates of MS 
by age was observed; females disclosed higher prevalence 
rates than males. Figure 3 illustrates the distribution of 
MS by country and gender. Chile and Colombia had the 
lowest prevalence rates of MS, while the remaining five 
countries showed comparable rates. Female patients 
of five countries; Brazil, Colombia, Ecuador, Peru and 
Venezuela had higher prevalence rates of MS than males, 
the opposite was observed in Argentina and Chile. 
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Table 1. Bivariate analysis of characteristics associated with metabolic syndrome* 
Characteristic Metabolic No metabolic Odd ratio p-value  
  syndrome syndrome (95% CI)
  (n = 812) (n = 3,198)  
Age, y 45.88 40.84 1.05 (1.04-1.06) < 0.001
Gender, %
 Male 19.37 80.63 1.0 
 Female 22.73 77.27 1.22 (1.03-1.45) 0.020
Family history of cardiovascular disease, %
 No 19.06 80.94 1.0 
 Yes 24.41 75.59 1.37 (1.15-1.64) < 0.001 
Duration of HIV infection, y 7.19 6.26 1.05 (1.03-1.07) < 0.001
Duration of combination antiretroviral treatment, y 3.87 2.76 1.08 (1.05-1.11) < 0.001
CD4 cell count, 103 cells/mm3 0.53 0.45 2.65 (2.03-3.46) < 0.001
Viral load, log
10
 copies/mL 2.27 2.37 0.90 (0.83-0.98) 0.011
Current protease inhibitor use, %
 No 17.85 82.15 1.0 
 Yes 23.27 76.73 1.40 (1.20-1.63) < 0.001
Current non-nucleoside reverse transcriptase inhibitor use, %
 No 22.75 77.25 1.0 
 Yes 18.29 81.71 0.76 (0.65-0.89)  0.001
Current nucleoside reverse transcriptase inhibitor use, %
 No 27.5 72.5 1.0 
 Yes 20.2  79.8 0.66 (0.29-1.51) 0.352
Body mass index, kg/m2 27.44 23.91 1.30 (1.27-1.33) < 0.001
Waist circumference, cm 96.05 85.45 1.11 (1.10-1.12) < 0.001
Obesity, %
 No 16.65 83.35 1.0 
 Yes 62.15 37.85 8.22 (6.44-10.48) < 0.001
Hypertension, %
 No 6.73 93.27 1.0 
 Yes 49.64 50.36 13.65 (11.34-16.44) < 0.001 
Elevated fasting blood glucose, %
 No 18.47 81.53 1.0 
 Yes 67.59 32.41 9.20 (6.44-13.15) < 0.001
Current smoking, %
 No 20.69 79.31 1.0 
 Yes 18.78 81.22 0.89 (0.74-1.07) 0.207
Lack of exercise, %
 No 18.59 81.41 1.0 
 Yes 21.70 78.30 1.21 (1.04-1.42) 0.015
Fasting serum glucose, mg/dL 106.69 88.77 1.04 (1.03-1.05) < 0.001
Fasting serum total cholesterol, mg/dL 209.0 192.19 1.01 (1.0-1.02) < 0.001
Fasting serum HDL, mg/dL 37.27 46.39 0.93 (0.92-0.94) < 0.001
Fasting serum LDL, mg/dL 114.3 109.1 1.03 (1.01-10.04) < 0.001
Fasting serum triglycerides, mg/dL 324.4 186.8 1.04 (1.03-1.05) < 0.001
*Values are mean unless noted otherwise
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The overall (SD) 10-year risk of developing CVD, as 
measured by the Framingham risk equation was 10.4% 
(24.7). Patients with MS had higher 10-year CVD risk 
compared to patients without MS: 22.2% vs. 7.4%, re-
spectively, p < 0.001. The bivariate analysis to identify 
determinants of MS is presented in Table 1. Patients 
with MS were older, had higher body mass index, more 
obesity and higher abdominal waist circumference than 
patients without MS. Most of the variables studied cor-
related with MS in this analysis including age, gender, 
family history of CVD, HIV related features such as 
duration of HIV infection, duration of ART, CD4 cell 
count and viral load, current use of PIs and NNRTIs, an-
thropometric data, lack of exercise, diabetes and hyper-
tension, as well as serum values of glucose and lipids. No 
association was found for current smoking and current 
use of NRTIs. We further explore the association of the 
most commonly used NRTIs in the region with MS, and 
confirmed no association for stavudine (OR: 0.93, 95% 
CI: 0.74-1.18, p = 0.600), abacavir (OR: 1.13, 95% CI: 
0.91-1.40, p = 0.263), and lamivudine (OR: 0.83, 95% 
CI: 0.65-1.06, p = 0.136), but a protective effect of zi-
dovudine was observed (OR: 0.820, 95% CI: 0.70-0.961, 
p = 0.016). 
The multivariate analysis is presented in Table 2. Age 
at enrollment (5.0% increase per year), female gender 
(28% increase), current use of PIs (33% increase), CD4 
cell count (9% increase per 100 cell raise) and family 
history of CVD (28% increase) correlated with meta-
bolic syndrome. The association of time living with HIV 
infection and time on ART, and the protective effect of 
zidovudine on MS were not confirmed in the multivari-
ate analysis. 
DISCUSSION
This cross sectional study analyzed pre-intervention 
data from the RAPID II study and demonstrates that 
Latin American HIV-infected patients receiving ART 
have a similar overall prevalence rate of MS than that 
reported from comparable populations in developed 
countries.9, 12-17 High triglycerides, low-HDL cholesterol, 
and hypertension were the most prevalent individual 
components of MS. Interestingly, female patients had 
higher prevalence rate of MS than males, with higher 
rates of abdominal obesity and lower-HDL cholesterol 
values than males. Patients with MS had higher risk of 
developing CVD and had nine fold higher prevalence of 
type 2 diabetes mellitus compared to patients without 
MS. We identified risk factors for MS including tradi-
tional hazards such as age and family history of CVD, 
and unique factors to this setting such as female gender, 
cellular immune-reconstitution and use of PIs. These 
finding are to our knowledge the first attempt to char-
acterize MS among HIV-infected patients on ART in the 
region and have important implications for designing 
regional preventive measures.
The prevalence of MS found in our study, 20.2%, is 
comparable to that reported from the developed world.9, 
12-17 Several studies have compared the prevalence of MS 
among HIV-infected and non-HIV infected patients, 
finding similar or higher prevalence rates among HIV 
infected patients.9,12,13 We did not include a non-HIV 
control group; therefore, we are not able to determine 
whether HIV-infected patients differ or not from the 
general population of Latin America. However, a recent-
ly published study in the region that recruited a large 
Table 2. Multivariate analysis of characteristics associated with metabolic syndrome*
Characteristic Adjusted 95% 
 Odds Ratio Confidence interval p-value
Age at enrollment, per year 1.05 1.04-1.06 < 0.001
Female gender 1.29 1.08-1.54 0.006
Family history of cardiovascular disease 1.28 1.07-1.54 0.007
CD4 cell count per 100 cell increase 1.09 1.06-1.12 < 0.001
Protease inhibitor based ART#  1.33 1.13-1.57 0.001
Zidovudine based ART 0.86 0.73-1.01  0.069
*corrected for anthropometric parameters, duration of HIV infection, time on antiretroviral treatment, viral load, smoking, 
hypertension, lack of exercise, and current use of nucleoside and non-nucleoside reverse transcriptase antiretroviral treatment.
# ART: antiretroviral therapy
MS in HIV-infected patients in Latin America
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sample size (11,500 subjects from six Latin American 
countries: Argentina, Colombia, Ecuador, Chile, Mexico 
and Peru) with a similar age distribution to our sam-
ple showed an overall prevalence rate of MS of 20%.18 
Interestingly, female subjects in that study had higher 
prevalence rate of MS than males (21.5% vs. 19.3%, re-
spectively), and disclosed similar gender differences in 
the prevalence of MS per country as seen in our study 
(higher female prevalence rate of MS in Ecuador, Peru 
and Colombia, and male predominance in Argentina). 
The authors attributed the difference to the growing 
diabetic and obesity pandemics in the region that affect 
mostly females. These data suggest that the prevalence 
of MS among HIV-infected patients in Latin America 
does not differ from the general population, but also 
suggest that different risk patterns may exist between 
these two populations. 
The most prevalent individual components of the 
MS in our study were high triglycerides, low-HDL cho-
lesterol and hypertension. This pattern has been consist-
ently seen across several studies in HIV-infected patients 
receiving ART.9,14,15 Gender differences in the frequency 
of each component of MS were observed in our study; 
males had higher frequency of elevated triglycerides, 
HBP and elevated blood glucose, while females had 
higher prevalence of low-HDL cholesterol and abdomi-
nal obesity. These gender differences in the contribution 
of each component of the MS have not been adequately 
explored in the literature, and may reflect real differ-
ences pertinent to the Latin American population that 
merit further investigation. Expectedly, MS patients 
had significantly higher 10-year risk of developing CVD 
compared to patients without MS as measured by the 
Framingham risk algorithm. 
Our study identified several independent risk fac-
tors for MS through multivariate analysis that control-
led for potential confounders. Among them, age and 
family history of CVD are well recognized risk factors 
for MS and CVD.9,14 We found a 9% increase in the risk 
of MS per 100 cell increment in CD4 cell count, imply-
ing that the most immune reconstituted patients had 
higher risk of developing MS. This finding is somewhat 
surprising, but has been observed by others.9,16,19 High-
er CD4 cell count was a predictor of MS in a cohort 
study of male HIV-infected patients,9 and more recent 
data from the DAD study (Data Collection on Adverse 
Events of Anti-HIV Drugs) found higher CD4 cell 
counts and lower viral load values among patients with 
MS.19 Similarly, a study conducted in Italy found that 
higher CD4 cell counts correlated with more CVD risk, 
hypothesizing that more immune-reconstituted pa-
tients represent a subset of patients with longer expo-
sure to ART showing cumulative higher risk of CVD.16 
Others have found that patients with higher CD4 cell 
counts (> 200 cells/mm3) had higher rates of vessel 
thickening, a surrogate marker for CVD, than patients 
with lower CD4 cell counts.20
Female gender was one of the strongest predictors 
of MS in our study, despite a male predominance in 
the sample population. While a very high prevalence 
of MS among females from the USA has been reported 
recently,21 this finding is rather unique in the literature, 
and may represent a distinctive feature of the Latin 
American region. A higher prevalence of MS among fe-
males in six Latin American countries has been reported 
recently, which may correspond with our findings,18 Un-
fortunately, the authors of that large study did not look at 
independent predictors of MS to confirm the presumed 
female predisposition. Finally, we found that HIV-related 
features such as time living with HIV and time on ART 
did not correlate with MS, but that a specific component 
of ART, current use of PIs independently correlated with 
MS, not finding an association with NRTI and NNRTI 
use. The literature has conflicting information regarding 
specific contribution of ART itself and its components 
to MS. Jacobson et al. found that ART did not correlate 
with MS.12 However, use of lopinavir/r boosted by riton-
avir and didanosine were independently associated with 
MS in the multivariate analysis in that study. In another 
study, Mondy et al. found that current use of ART was 
not different in subjects with and without MS, but use of 
PIs was associated with higher triglyceride levels only.9 
Another study conducted in Spain found that past and 
current use of a PI correlated with MS; that study also 
found that current use of stavudine correlated with MS.8 
These dissimilar findings may be explained by different 
patterns of lipid derangements associated with specific 
components of ART, including thymidine analogues and 
PIs, in particular with ritonavir-boosted PI regimens, 
but may also be explained by different patient popula-
tions and probably by gender and race differences that 
have not been adequately explored. 
Our study has limitations including the non-random 
selection of the study participants that may affect the 
representativeness of the sample, and the absence of 
controls from the general population, that makes dif-
ficult to draw conclusions regarding the significance of 
our data. On the other hand, the large sample size, and 
the participation of patients from seven countries that 
collectively manage the largest number of HIV-infected 
patients in South America are strengths of the study. Ad-
ditionally, the findings of similar results for the overall 
prevalence of MS and for the higher prevalence of MS 
among females, when compared to a larger study con-
ducted among non-HIV subjects from the region pro 
vide further support on the relevance of the information 
Alvarez, Salazar, Galindez et al.
262
presented here. The cohort design of the RAPID II study 
will allow us to corroborate the results obtained in this 
cross sectional study, in particular to evaluate the inci-
dence of MS, to provide more information on the con-
tribution of individual components of the syndrome, 
and to compare its predictive value in calculating CVD 
risk compared to other available risk determinations. 
In conclusion, the prevalence of MS in this large 
group of HIV-infected patients receiving ART is com-
parable to that reported from similar populations from 
developed countries and from non-HIV infected sub-
jects from the region. Patients with MS had higher esti-
mated risk for CVD. MS was associated with traditional 
risk factors but with somewhat unique features such as 
female gender, immune-reconstitution and current PI 
use. Latin American physicians should be aware of the 
magnitude of the problem, and should incorporate into 
daily practice interventions to reduce MS, targeting the 
risk groups identified in this study.
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